Citius Oncology (CTOR) Other Accumulated Expenses (2023 - 2026)

Citius Oncology (CTOR) has reported Other Accumulated Expenses for 4 consecutive years, with $10.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Other Accumulated Expenses rose 33.78% year-over-year to $10.0 million in Q2 2026; TTM through Jun 2026 was $10.0 million, a 33.78% increase from a year earlier, with the FY2025 full-year figure at $9.5 million, up 1515.77% from the prior year.
• Other Accumulated Expenses was $10.0 million for Q2 2026 at Citius Oncology, up from $8.2 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $19.5 million in Q3 2023 and troughed at $344875.0 in Q4 2023.
• A 4-year average of $5.9 million and a median of $4.9 million in 2025 frame the typical range for Other Accumulated Expenses.
• Across the five-year window, Other Accumulated Expenses plunged 96.98% in 2024 and soared 1515.77% in 2025, its largest moves.
• Over 4 years, Other Accumulated Expenses stood at $344875.0 in 2023, then jumped by 739.82% to $2.9 million in 2024, then soared by 296.87% to $11.5 million in 2025, then dropped by 13.13% to $10.0 million in 2026.
• The last three Other Accumulated Expenses figures came in at $10.0 million (Q2 2026), $8.2 million (Q1 2026), and $11.5 million (Q4 2025), per Business Quant data.